

TABLE 3
Biogen Idec Inc.
March 31, 2010
Condensed Consolidated Statements of Income - Non-GAAP
(in millions, except per share amounts)
(unaudited)

EARNINGS PER SHARE	Three Months Ended March 31,	
	2010	2009
GAAP earnings per share - Diluted	\$ 0.80	\$ 0.84
Adjustments to net income attributable to Biogen Idec Inc. (as detailed below)	0.28	0.21
Non-GAAP earnings per share - Diluted	\$ 1.08	\$ 1.05

An itemized reconciliation between net income attributable to Biogen Idec Inc. on a GAAP basis and net income attributable to Biogen Idec Inc. on a non-GAAP basis is as follows:

GAAP net income attributable to Biogen Idec Inc.	\$ 217.4	\$ 244.0
Adjustments:		
R&D: Restructuring and severance	0.6	1.0
R&D: Stock option expense	1.6	2.2
R&D: Expenses paid by Cardiokine	1.8	1.6
SG&A: Restructuring and severance	4.3	0.1
SG&A: Stock option expense	10.8	4.5
Amortization of acquired intangible assets	48.9	89.2
Acquired in-process research and development related to the contingent consideration payment made associated with the 2007 Syntonix acquisition	40.0	-
Income tax expense: Income tax effect primarily related to reconciling items	(27.2)	(35.4)
Noncontrolling interest: Expenses paid by Cardiokine	(1.8)	(1.6)
Non-GAAP net income attributable to Biogen Idec Inc.	\$ 296.4	\$ 305.6

Use of Non-GAAP Financial Measures

Our "non-GAAP net income attributable to Biogen Idec, Inc." and "non-GAAP diluted EPS" financial measures exclude the following items from GAAP net income attributable to Biogen Idec, Inc. and diluted EPS:

1. Purchase accounting and merger-related adjustments.

We exclude certain purchase accounting impacts, such as those related to the 2003 merger between Biogen, Inc. and Idec Pharmaceuticals, Inc., the acquisitions of Fumapharm AG, Conforma Therapeutics and Syntonix Pharmaceuticals, and the consolidation of Cardiokine and Neurimmune. These include charges for in-process research and development and the incremental charges related to the amortization of the acquired intangible assets. Excluding these charges provides management and investors with a supplemental measure of performance in which the Company's acquired intellectual property is treated in a comparable manner to its internally developed intellectual property.

2. Stock option expense recorded in accordance with the accounting standard for share-based payments.

We believe that excluding the impact of expensing stock options better reflects the recurring economic characteristics of our business. We also exclude stock option expense from our non-GAAP R&D expenses and SG&A expenses, but include P&L impact of restricted stock grants and cash incentives in our non-GAAP results.

3. Unusual or non-recurring items.

We evaluate these on an individual basis, and consider both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis.

We believe it is important to share these non-GAAP financial measures with shareholders as they better represent the ongoing economics of the business, reflect how we manage the business internally and set operational goals, and form the basis of our management incentive programs. Non-GAAP net income attributable to Biogen Idec, Inc. and diluted EPS should not be viewed in isolation or as a substitute for reported, or GAAP, net income attributable to Biogen Idec, Inc. and diluted EPS.